Novartis will pay up to $3.5 billion for Chinook Therapeutics for its pipeline of two high-value late-stage medicines for the treatment of rare, severe chronic kidney disease.
Source: Drug Industry Daily
Novartis will pay up to $3.5 billion for Chinook Therapeutics for its pipeline of two high-value late-stage medicines for the treatment of rare, severe chronic kidney disease.
Source: Drug Industry Daily